The cytochrome P450 system and adverse drug reactions

Adverse Drug Reaction Bulletin

Volumn , Issue 194, 1999, Pages 739-742

  Shenfield, Gillian ^a   Gross, Annette ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CODEINE; CYTOCHROME P450; ERYTHROMYCIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; MEVINOLIN; MOCLOBEMIDE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PERHEXILINE; PHENFORMIN; PROTEINASE INHIBITOR; SIMVASTATIN; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ADVERSE DRUG REACTION; BLEEDING; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOXICITY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; ENZYME SUBSTRATE COMPLEX; FRUIT JUICE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LACTIC ACIDOSIS; LIVER TOXICITY; NEPHROTOXICITY; SEIZURE; SHORT SURVEY; TORSADE DES POINTES;

EID: 0032900840     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-199902000-00001     Document Type: Short Survey

References (52)

1. Gonzales FJ. Human cytochromes P450: problems and prospects. Trends in Pharmacological Sciences 1992; 13: 346-52.
2. Shen WW. Cytochrome P450 monooxygenases and interactions of psychtropic drugs: a five-year update. International Journal of Psychiatry in Medicine 1995; 25: 277-90.
3. Nebert DW. Clinical Pharmacology. Possible clinical importance of genetic differences in drug metabolism. British Medical Journal Clinical Research Edition 1981; 283; 537-42.
4. Nelson DR, Koymans L, Kamataki T. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
5. Bickett DJ, MacKenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends in Pharmacological Sciences 1993; 14: 292-94.
6. Idle JR, Smith RL. Pharmacogenetics in the new patterns of healthcare delivery. Pharmacogenetics 1995; 5: 347-50.
7. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacology and Therapeutics 1990; 46: 377-94.
8. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. Journal of Pharmacy and Pharmacology 1994; 46 Suppl 1: 409-15.
9. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 1989; 36: 537-547.
10. Miners JO, Bickett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998; 6: 525-38.
11. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-52.
12. Meyer UA. Genetic polymorphisms of drug metabolism. Fundamental and Clinical Pharmacology 1990; 4: 595-615.
13. Guengerich FP. Polymorphism of Cytochrome P-450 in humans. Trends in Pharmacological Science 1989; 10: 107-9.
14. Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. British Journal of Clinical Pharmacology 1998; 46: 499-504.
15. Steijns LSW, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clinical Chemistry 1998; 44: 914-17.
16. Bathum L, Johansson I, Ingleman-Sundberg M, Horder M, Brøsen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction frequent length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119-23.
17. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics 1991; 20: 350-73.
18. Chan E, Ti TY, Lee HS. Population pharmacokinetics of phenytoin in Singapore Chinese. European Journal of Clinical Pharmacology 1990; 39: 177-81.
19. Weibert RT, Palinkas LA. Differences in warfarin dose requirements between Asian and Caucasian patients. Clinical Pharmacology and Therapeutics 1991; 49: 157.
20. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63.
21. Leonard MS. Genetically determined adverse drug reactions involving metabolism. Drug Safety 1993; 9: 60-77.
22. Bertilsson L, Dahl ML, Sjöqvist F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.
23. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris - correlations with pharmacokinetics. International Journal of Cardiology 1986; 13: 219-29.
24. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clinical Pharmacology and Therapeutics 1983; 34: 827-34.
25. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European Journal of Clinical Pharmacology 1996; 51: 289-95.
26. Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33.
27. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405-9.
28. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clinical Pharmacology and Therapeutics 1998; 63: 519-28.
29. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9. Methods in Enzymology 1996; 272: 139-45.
30. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation 1992; 90: 1871-8.
31. de Waziers I, Cugnenc PH, Yan CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. Journal of Pharmacology and Experimental Therapeutics 1990; 253: 387-94.
32. Back DJ, Grimmer SFM, Orme ML'E, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anti-convulsants and antibiotics. British Journal of Clinical Pharmacology 1988; 25: 527-32.
33. Lin JH, Lu AYH. Inhibition and Induction of Cytochrome P450 and the Clinical Implications. Clinical Pharmacokinetics 1998; 35: 361-90.
34. Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine. Clinical Pharmacokinetics 1987; 12: 321-66.
35. Schlanz KD, Myre SA, Bottrff MB. Pharmacokinetic interactions with calcium channel antagonists (part II). Clinical Pharmacokinetics 1991; 21: 448-60.
36. Jones TE, Morris RG, Mathew TH. Diltiazemcyclosporin pharmacokinetic interaction-dose-response relationship. British Journal of Clinical Pharmacology 1997; 44: 499-504.
37. Azie NE, Brater DC, Becker PA , Jones DR, Hall SB. The interaction of diltiazem with lovastatin and pravastatin. Clinical Pharmacology and Therpeutics 1998; 64: 369-77.
38. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. Journal of the American Medical Association 1993; 269: 1513-18.
39. Crane JK, Shih H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. American Journal of Medicine 1993; 95: 445-6.
40. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics 1992; 52: 231-8.
41. Veronese ME, Miners JO, Randles D, Birkett DJ. Validation of the tolbutamide metabolite ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical Pharmacology and Therapeutics 1990; 47: 403-11.
42. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics 1990; 47: 79-85.
43. Sproule BA, Narango CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics 1997; 33: 454-71.
44. Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-23.
45. Lundahl J, Regardh CC, Edgar B, Johnsson G. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. European Journal of Clinical Pharmacology 1997; 52: 139-45.
46. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clinical Pharmacology and Therapeutics 1995; 57: 485-91.
47. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice - drug interactions. British Journal of Clinical Pharmacology 1998; 46: 101-10.
48. James JS. Grapefruit juice and saquinavir. AIDS Treatment News 1995; 235: 5-6.
49. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. Journal of the American Medical Association 1994; 272: 1845-50.
50. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology 1996; 24: 45-57.
51. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Therapeutic Drug Monitoring 1998; 20: 517-24.
52. Richelson E. Pharmacokinetic interactions of anti-depressants. Journal of Clinical Psychiatry 1998; 59 (suppl 10): 22-6.